Appendix 4D

SIRTEX MEDICAL LIMITED

ABN 35 078 166 122

Interim report – half year ended 31 December 2013

(Previous corresponding period: half year ended 31 December 2012)

Results for announcement to the market

	% change	$ 000
Revenue from ordinary activities	up 27.2 %	58,581
Profit from ordinary activities after tax attributable to members	up 43.6 %	11,170
Total comprehensive income for the period attributable to members	up 56.4 %	12,260

Dividends (Distributions)

	2013	2012
Final dividend (paid on 25 October 2013 for financial year ended 30 June 2013)		
amount per security	12.0 cents	10.0 cents
franked amount per security	12.0 cents	10.0 cents
Interim dividend		
amount per security	Nil	Nil
franked amount per security	Nil	Nil

NTA Backing

	2013	2012
Net tangible asset backing per ordinary security	93.6 cents	94.4 cents

ASX / Media Release **18th February 2014**

SIRTEX PROFIT AFTER TAX UP 44 PER CENT FOR HALF YEAR

- **Net profit after tax (NPAT) increased 43.6 per cent to $11.2 million**
- **Global dose sales growth of 11.3 per cent to 3,919 units**
- **Revenue from sale of goods improved 27.2 per cent to $58.6 million**
- **Cash from operating activities increased 20.5 per cent to $15.9 million**
- **Fully Franked Dividend of 12 cents per share paid 25th October 2013**

Sirtex Half Year Financial Results Summary

	1H 2014 $ '000	**1H 2013** $ '000	% change
Dose sales	3,919 units	3,522 units	+11.3%
Revenue from sale of goods	58,581	46,042	+27.2%
Profit before tax	14,594	10,710	+36.3%
Profit after tax	11,170	7,780	+43.6%
Cash at end of the half year*	47,850	50,993	-6.2%
Net cash flow from operations	15,892	13,183	+20.5%
Dividend per share paid	12 cents	10 cents	+20.0%
Capitalised Intangible Assets	9,899	4,914	+101.4%
Capitalised Tangible Assets	3,502	1,231	+183.8%

* Including cash on deposit for greater than 90 days.

Sirtex Medical Limited (ASX: SRX) today announced half year results for the period ended 31st December 2013 demonstrating solid financial performance and continued dose sales growth of its SIR-Spheres® microspheres targeted radiotherapy treatment for liver cancers.

The results reaffirm the company's *2020Vision* strategy of making appropriate investments in sales and marketing infrastructure, operations and clinical studies to build a robust oncology company with sustainable long term growth prospects.

Revenue from sale of goods was $58.6 million, up 27.2 per cent from $46.0 million in the previous corresponding period. The revenue improvement was driven by volume growth of 11.3 per cent and the depreciation of the Australian Dollar by approximately 16 per cent compared to the same period last year.

Net profit after tax (NPAT) was $11.2 million, up 43.6 per cent on the same period last year. Pre-tax profit was up 36.3 per cent from $10.7 million to $14.6 million.

Strong global sales growth continues

Global dose sales were up 11.3 per cent to 3,919 units compared to 3,522 for the same period last year.

The Americas dose sales of 2,648 rose 14.9 per cent. Dose sales in the APAC (Asia Pacific) of 397 increased 14.4 per cent compared to the same period last year. Dose sales in EMEA (Europe, Middle East and Africa) of 874 were up 0.5 per cent compared to the same period last year.

Dose sales growth in the Americas was a direct result of increased investment and effectiveness in sales and marketing. The team continues to make steady progress, working closely with the referral community to make sure that the potential benefits of SIR-Spheres microspheres is widely understood. Geographic growth is also progressing with Sirtex recently granted regulatory approval to sell in Brazil.

APAC sales continue to grow by adopting a direct sales model in various countries through Sirtex's Singapore regional head office. Improved management of distributors in Taiwan, South Korea and India enhanced pricing and volumes.

EMEA dose sales maintained their market position despite lower demand in the UK due to short term reimbursement changes and continued economic uncertainty throughout the European Union. The team in EMEA is confident sales momentum will improve and medical demand for SIR-Spheres microspheres remains strong. SIR-Spheres microspheres is now reimbursed in Israel.

Sirtex's investment in sales and marketing grew 33.1 per cent to $21.2 million during the period as the company continued to make good progress in its efforts to expand awareness and the use of SIR-Spheres microspheres among the global oncology community.

Clinical strategy investment to deliver future growth

A key initiative of Sirtex's 2020Vision strategy is its clinical studies program comprising 6 major studies. The goal of the clinical studies program is to provide the medical community with the required Level 1 data that demonstrates SIR-Spheres microspheres is an effective treatment option for patients at an earlier stage of their disease rather than as a treatment of last resort

Global Clinical Studies Recruitment Progress

Study Name	Start	Total Patients	% Recruited @ 31 Dec 2012	% Recruited @ 30 Jun 2013	% Recruited @ 31 Dec 2013	Type of Liver Cancer
SIRFLOX	2006	532	94%	100%	100%	mCRC
FOXFIRE FOXFIRE Global	2010	490	35%	46%	68%	mCRC
SARAH	2012	400	20%	44%	67%	HCC
SORAMIC	2010	375	30%	41%	53%	HCC
SIR*ve*NIB	2011	360	43%	53%	64%	HCC

Investment aimed at progressing the clinical studies increased 63.1 per cent to $11.4 million ($8.6 million capitalised and $2.8 million to P&L).

Importantly, the preliminary results of the company's flagship SIRFLOX study in metastatic colorectal cancer (mCRC) are now expected to be available in the first quarter of calendar 2015. Detailed results of the study should be available for presentation by the principal investigators to the medical community at the American Society of Clinical Oncology (ASCO) in May/June 2015. Such presentation at a major scientific congress is a necessary and critical step in the validation and subsequent acceptance of the results by the broader medical community.

The SARAH study in hepatocellular carcinoma (HCC) over the past six months continued to recruit rapidly adding 93 patients. At the end of December 2013, the study had recruited 67 per cent of the required patients. Sirtex expects recruitment to be completed during the last quarter of calendar 2014.

Operating expenses

Sirtex's *2020Vision* involves building capability and capacity for future growth, not only in sales and marketing but also in the business support functions of operations, medical, regulatory affairs, quality and general administration. Accordingly total operating expenses increased 26.5 per cent to $35.3 million compared to $27.9 million in the previous corresponding period. Staff numbers increased 28.3 per cent over the last 12 months.

Additionally, Sirtex invested a further $3.5 million in the expansion of its manufacturing in the United States and the establishment of manufacturing facilities in Germany. The development of both facilities is progressing to plan.

Investment in research and development

Research and development investment was up 34.8 per cent to $4.0 million ($1.3 million capitalised and $2.7 million to P&L) in the first half of the 2014 financial year. Our primary R&D focus is on our SIR-Spheres Evolution Program which is aimed to help support long term sales growth by delivering useful new product enhancements. This is being achieved by addressing how to make the company's core product even more effective in the clinic and easier to use by a wider number of medical specialists. Based on the positive results to date, the company has accelerated these development programs.

Looking to the future Sirtex has also invested in a pipeline of promising new technologies which comprise two different nano technology platforms and also a radioprotector technology. These technologies have the potential to be developed into new products to address unmet medical needs and further expand the business.

Cash management and dividend

Cash from operating activities was up 20.5 per cent from $13.2 million to $15.9 million. A fully franked dividend of 12 cents per share for the 2013 financial year was paid on 25th October 2013. This equated to a payment of $6.7 million and is Sirtex's fifth consecutive year of dividend payments.

Sirtex remains debt free and at the end of December 2013 the company's cash balance, including term deposits over 90 days, was $47.8 million ($51.0 million, December 2012). Capital expenditure, excluding the capitalisation of intangible assets, for the period was $3.5 million. The majority of this was investment in the expansion of manufacturing capacity and capabilities.

Foreign exchange

Foreign exchange movements continued to influence Sirtex's financial results as the company earns over 95 per cent of its revenue overseas. During the reporting period, the Australian dollar depreciated 15 per cent against the US dollar and 19 per cent against the Euro compared to the same period last year.

A very positive outlook

Sirtex's business outlook in all geographic markets remains positive. There is a significant unmet global medical need for Sirtex's liver cancer therapy which will continue to drive demand in new and established markets over the long term. Sirtex's *2020Vision* is focused on rapidly expanding the business through continued investment in its resources and capabilities backed by a promising new product pipeline to create a solid foundation for long term growth.

For further information please contact:

Gilman Wong - CEO	Tim Allerton or Andrew Geddes
Sirtex Medical Limited	City Public Relations
+61 (02) 9964 8400	+61 (02) 9267 4511

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

Interim Financial Report

FOR THE HALF-YEAR ENDED 31 DECEMBER 2013

SIRTEX MEDICAL LTD AND ITS CONTROLLED ENTITIES
ABN 35 078 166 122

Directors' Report

for the half-year ended 31 December 2013

Your directors submit the financial report of the consolidated entity for the half-year ended 31 December 2013.

Directors

The names of directors who held office during or since the end of the half-year:

R. Hill (Non-executive director, Chairman)

Dr J. Eady (Non-executive director, Deputy Chairman)

G. Boyce (Non-executive director)

G. Wong (Executive director, Chief Executive Officer)

Review of Operations

Sirtex Medical Ltd and its controlled entities are a biotechnology and medical device group whose primary objective is to manufacture, distribute and conduct R&D leading to commercialisation of effective liver cancer treatments utilising novel small particle technology to a number of approved markets in APAC (Asia-Pacific), EMEA (Europe, Middle East, and Africa), and the Americas.

Consistent with last year, expenses for certain clinical activities have been capitalised as they continue to satisfy the recognition criteria for internally generated intangible assets.

Rounding of Amounts

The consolidated entity has applied the relief available to it in ASIC Class Order 98/100 and accordingly certain amounts in the financial report and the directors' report have been rounded off to the nearest $1,000.

Events after Reporting Date

No matters or circumstances have arisen since the end of the half year, that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

Auditor's Independence Declaration

The lead auditor's independence declaration under section 307C of the Corporations Act 2001 is set out on page 3 for the half year ended 31 December 2013 and forms part of this report.

This report is signed in accordance with a resolution of the Board of Directors.

Gilman Wong
Director
18 February 2014

Grant Thornton

Grant Thornton Audit Pty Ltd
ACN 130 913 594

Level 17, 383 Kent Street
Sydney NSW 2000
PO Locked Bag Q800
QVB Post Office
Sydney NSW 1230

T +61 2 8297 2400
F +61 2 9299 4445
E info.nsw@grantthornton.com.au
W www.grantthornton.com.au

Auditor's Independence Declaration
To the Directors of Sirtex Medical Limited

In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of Sirtex Medical Limited for the half-year ended 31 December 2013, I declare that, to the best of my knowledge and belief, there have been:

a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and

b no contraventions of any applicable code of professional conduct in relation to the review.

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

N J Bradley
Partner – Audit and Assurance

Sydney, 18 February 2014

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.

Directors' Declaration **for the half-year ended 31 December 2013**

The directors of the company declare that:

1. The consolidated financial statements and notes, as set out on page 7 to 16, are in accordance with the Corporations Act 2001, including:
   a. complying with Accounting Standard AASB 134: Interim Financial Reporting; and
   b. giving a true and fair view of the consolidated entity's financial position as at 31 December 2013 and of its performance for the half year ended on that date.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Gilman Wong
Director
18 February 2014

Grant Thornton Audit Pty Ltd
ACN 130 913 594

Level 1,
67 Greenhill Rd
Wayville SA 5034
GPO Box 1270
Adelaide SA 5001230

T +61 8297 2400
F +61 9299 4445
E info@gtsa.com.au
W www.grantthornton.com.au

Independent Auditor's Review Report
To the Members of Sirtex Medical Limited

We have reviewed the accompanying half-year financial report of Sirtex Medical Limited ("Company"), which comprises the consolidated financial statements being the statement of financial position as at 31 December 2013, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a statement or description of accounting policies, other explanatory information and the directors' declaration of the consolidated entity, comprising both the Company and the entities it controlled at the half-year's end or from time to time during the half-year.

Directors' responsibility for the half-year financial report

The directors of Sirtex Medical Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such controls as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the consolidated half-year financial report based on our review. We conducted our review in accordance with the Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the Sirtex Medical Limited consolidated entity's financial position as at 31 December 2013 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of Sirtex Medical Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Sirtex Medical Limited is not in accordance with the Corporations Act 2001, including:

a giving a true and fair view of the consolidated entity's financial position as at 31 December 2013 and of its performance for the half-year ended on that date; and

b complying with Accounting Standard AASB 134 Interim Financial Reporting and Corporations Regulations 2001.

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

N J Bradley
Partner – Audit & Assurance

Sydney, 18 February 2014

Consolidated Statement of Profit or Loss and Other Comprehensive Income

for the half-year ended 31 December 2013

		Consolidated	
		2013	2012
	Note	$'000	$'000
Revenue from the sale of goods		58,581	46,042
Cost of sales		(9,234)	(8,473)
Gross profit		**49,347**	**37,569**
Other revenue		1,035	1,312
Marketing expenses		(21,194)	(15,922)
Research expenses		(2,717)	(2,536)
Regulatory expenses		(424)	(384)
Quality assurance expenses		(701)	(571)
Clinical expenses		(2,782)	(2,500)
Medical expenses		(1,211)	(881)
Administration expenses		(6,249)	(5,092)
Other expenses		(1,007)	(201)
Foreign exchange gains / (losses)		497	(84)
Profit before income tax expense	3	**14,594**	**10,710**
Income tax expense		(3,424)	(2,930)
Profit attributable to members of the parent entity		**11,170**	**7,780**
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss			
Change in foreign exchange translation reserve		281	60
Items that will not be reclassified subsequently to profit and loss			
Deferred tax income		809	-
Total comprehensive income attributable to members of the parent entity		**12,260**	**7,840**
Earnings per share		**Cents**	**Cents**
Basic earnings per share		19.9	14.0
Diluted earnings per share		19.5	13.6

The financial statements should be read in conjunction with the accompanying notes

Consolidated Statement of Financial Position

as at 31 December 2013

	Note	Consolidated 31 Dec 13 $'000	Consolidated 30 Jun 13 $'000
CURRENT ASSETS			
Cash and cash equivalents		13,850	20,094
Other short-term deposits		34,000	32,000
Trade and other receivables		20,470	20,645
Inventories		1,745	1,690
Financial assets		1,347	680
Other assets		2,661	2,223
Current tax assets		689	-
Total - CURRENT ASSETS		**74,762**	**77,332**
NON-CURRENT ASSETS			
Property, plant and equipment		11,969	9,129
Intangible assets	2	38,179	28,376
Deferred tax assets		3,522	2,930
Total - NON-CURRENT ASSETS		**53,670**	**40,435**
TOTAL ASSETS		**128,432**	**117,767**
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables		12,852	11,076
Current tax liabilities		-	1,895
Short-term provisions		8,408	6,855
Total - CURRENT LIABILITIES		**21,260**	**19,826**
NON-CURRENT LIABILITIES			
Long-term provisions		845	831
Deferred tax liabilities		12,082	8,972
Total - NON-CURRENT LIABILITIES		**12,927**	**9,803**
TOTAL LIABILITIES		**34,187**	**29,629**
NET ASSETS		**94,245**	**88,138**
EQUITY			
Issued capital		24,229	23,521
Reserves		2,336	2,183
Retained earnings		67,680	62,434
TOTAL EQUITY		**94,245**	**88,138**

The financial statements should be read in conjunction with the accompanying notes

Consolidated Statement of Changes in Equity

for the half-year ended 31 December 2013

	Ordinary Shares $'000	Share rights Reserve $'000	FX Translation Reserve $'000	Retained Profits $'000	Total $'000
Balance at 1 July 2012	**23,521**	**750**	**(463)**	**49,740**	**73,548**
Total comprehensive income for the period	-	-	60	7,780	7,840
Contribution to Performance Rights Reserve	-	557	-	-	557
Dividends paid or provided for	-	-	-	(5,576)	(5,576)
Balance at 31 December 2012	**23,521**	**1,307**	**(403)**	**51,944**	**76,369**
Balance at 1 July 2013	**23,521**	**1,998**	**185**	**62,434**	**88,138**
Total comprehensive income for the period	-	-	281	11,979	12,260
Ordinary shares issued	708	(708)	-	-	-
Contribution to Performance Rights Reserve	-	580	-	-	580
Dividends paid or provided for	-	-	-	(6,733)	(6,733)
Balance at 31 December 2013	**24,229**	**1,870**	**466**	**67,680**	**94,245**

The financial statements should be read in conjunction with the accompanying notes

Consolidated Statement of Cash Flows

for the half-year ended 31 December 2013

	Consolidated	
	2013	2012
	$'000	$'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	59,082	46,256
Payments to suppliers and employees	(39,158)	(31,643)
Interest received	1,162	1,054
Net income tax paid	(5,194)	(2,484)
Net cash provided by operating activities	**15,892**	**13,183**
CASH FLOWS FROM INVESTING ACTIVITIES		
Receipts from other short-term deposits	(2,000)	4,000
Purchase of plant and equipment	(3,503)	(1,231)
Internally generated intangible assets	(9,899)	(4,912)
Net cash used in investing activities	**(15,402)**	**(2,143)**
CASH FLOWS FROM FINANCING ACTIVITIES		
Payment of dividends	(6,733)	(5,494)
Net cash used in financing activities	**(6,733)**	**(5,494)**
Increase / (Decrease) in cash held	**(6,243)**	**5,546**
Cash at beginning of the financial period (1)	**20,094**	**13,447**
Cash at end of the financial period (1)	**13,851**	**18,993**

(1) Cash at the end of the financial period excludes term deposits held with a maturity date of greater than 90 days after the end of the financial period. These are described as “other short term deposits” in the Consolidated Statement of Financial Position.

The financial statements should be read in conjunction with the accompanying notes

Notes to the Financial Statements

for the half-year ended 31 December 2013

NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

These general purpose financial statements for the interim half-year reporting period ended 31 December 2013 have been prepared in accordance with requirements of the *Corporations Act 2001* and Australian Accounting Standards including AASB 134: Interim Financial Reporting, and are presented in Australian dollar ($), which is the functional currency of the parent company.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Sirtex Medical Limited and its controlled entities (the Group). They do not include all of the information required in annual financial statements in accordance with Australian Accounting Standards, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2013 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Stock Exchange Listing Rules and the *Corporations Act 2001*.

New and revised accounting standards

The Group has adopted all new and revised Australian Accounting Standards and Interpretations that became effective for the first time and are relevant to the Group, including:

AASB 2011-9 *Amendments to Australian Accounting Standards – Presentation of Items of Other Comprehensive Income* which requires entities to group items presented in Other Comprehensive Income (OCI) on the basis of whether they are potentially reclassifiable to profit and loss subsequently, and changes the title of "Statement of Comprehensive Income" to Statement of Profit or Loss and Other Comprehensive Income".

The adoption of the new and revised Australian Accounting Standards and Interpretations has had no impact on the Group's accounting policies or the amounts reported during the current half-year period. The adoption of AASB 2011-9 has resulted in the title of "Statement of Comprehensive Income" being changed to "Statement of Profit or Loss and Other Comprehensive Income".

AASB 2010 *Consolidated Financial Statements* which supersedes AASB 127 *Consolidated and Separate Financial Statements*. AASB 10 revises the definition of control and provides extensive new guidance on its application. These new requirements have the potential to affect which of the Group's investees are considered to be subsidiaries and therefore change the scope of consolidation. The requirements on consolidation procedures, accounting for changes in non-controlling interests and accounting for loss of control of a subsidiary are unchanged.

The adoption of this new Australian Accounting Standard has no effect on the classification of any of the Group's investees held during the period or comparative periods covered by these financial statements.

AASB 119 *Employee Benefits* which makes a number of changes to the accounting for employee benefits, the most significant relating to defined benefit plans.

The adoption of this new Australian Accounting Standard has no effect on the profit or loss and other comprehensive income for the period, and has no effect on the statement of financial position at 31 December 2013 and 30 June 2013.

Estimates

When preparing the interim financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management. The judgements, estimates and assumptions made during the period ended 31 December 2013 were the same as those applied in the Group's last financial statements for the year ended 30 June 2013.

These financial statements were authorised for issue by the Board of Directors on 18 February 2014.

NOTE 2: INTANGIBLE ASSETS

Internally generated intangible assets

Internally generated intangible assets include five major Phase IV post-marketing clinical trials and two development projects aiming to improve the ease of use of Sir-Spheres microspheres. As these activities satisfy the recognition criteria as set out below, expenses incurred during the half year for these activities have been classified as internally generated intangible assets and capitalised in the Statement of Financial Position, for a total of $9,899,110.

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised if, and only if all of the following is demonstrated:

- The technical feasibility of completing the intangible asset so that it will be available for use or for sale
- The intention to complete the intangible asset and to use it or sell it
- The ability to use or to sell the intangible asset
- The intangible asset will generate future economic benefits
- Adequate technical, financial, and other resources to complete the development and to use or sell the intangible asset are available
- The expenditure attributable to the intangible asset during its development can be reliably measured

Following the initial recognition of the development expenditure, the cost model is applied requiring the assets to be carried at cost less accumulated impairment losses. Current capitalised development costs are to be amortised over 7 years.

The Consolidated Entity uses its judgment in continually assessing whether development expenditure meet the recognition criteria on an intangible asset.

At 31 December, the assessment of all development activities resulted in the recognition of certain development expenditure as an internally generated intangible asset.

The carrying value of an intangible asset arising from development costs is tested for impairment annually when the asset is not yet available for use or more frequently when an indicator of impairment arises during the reporting period.

	Consolidated	
	31 Dec 13 $'000	30 Jun 13 $'000
Total intangible assets		
At cost	41,721	31,822
Accumulated amortisation	(3,542)	(3,446)
Net carrying amount	38,179	28,376
Movements in carrying amounts		
Total intangible assets		
Carrying amount at beginning	28,376	16,082
Additions	9,899	12,501
Amortisation expense	(96)	(207)
Carrying amount at end	38,179	28,376

Notes to the Financial Statements

for the half-year ended 31 December 2013

NOTE 3: PROFIT FOR THE PERIOD

	Consolidated	
	31 Dec 13 $'000	**31 Dec 12 $'000**
Profit before income tax includes the following items of income / (expenses):		
Cost of sales	(9,234)	(8,473)
Bad and doubtful debts expense	(1,005)	(198)
Depreciation and amortisation of		
plant and equipment	(663)	(593)
intangible assets	(96)	(104)
Operating lease expenses		
minimum lease payments	(596)	(451)
Foreign exchange gains / (losses)		
Realised foreign exchange gains	(54)	8
Unrealised foreign exchange gains / (losses)	551	(92)

NOTE 4: SHARE CAPITAL

During the period ended 31 December 2013, a total of 340,303 shares were issued as a result of the exercise of performance rights vested. The weighted average share price at the date of issue was $12.33 (2012: $nil). Each share has the same right to receive dividends and the repayment of capital and represents one vote at the shareholders' meeting. Shares issued and authorised are summarised as follows:

	Consolidated	
	6 months to 31 Dec 13	**6 months to 31 Dec 12**
Shares issued and fully paid:		
Beginning of the period	55,768,136	55,768,136
Issued under share-based payment plans	340,303	-
Shares issued and fully paid	**55,108,439**	**55,768,136**
Total shares authorised at the end of the period	**56,108,439**	**55,768,136**

NOTE 5: DIVIDENDS

	Consolidated	
	31 Dec 13 $'000	**31 Dec 12 $'000**
Distributions paid/provided for		
Fully franked ordinary dividend paid on 25 October 2013 of 12 cents (2012: 10 cents) per share	6,733	5,576

Notes to the Financial Statements

for the half-year ended 31 December 2013

NOTE 6: OPERATING SEGMENT

Identification of reportable segments
The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors in assessing performance and determining the allocation of resources.

The Group is managed primarily on the basis of regional markets which have different structures and performance as assessment criteria. Operating segments are therefore determined on the same basis. The three regional markets currently serviced by the group are Asia Pacific, North and South America (Americas) and Europe, Middle East, and Africa.

As the group manufactures and distributes only one product, identical for each of the three regional markets, no further segmentation across products or services is made.

Basis of accounting for purposes of reporting by operating segments

Accounting policies adopted
Unless stated otherwise, all amounts reported to the Board of Directors with respect to operating segments are determined in accordance with accounting policies that are consistent to those adopted in the annual financial statements of the Group.

Inter-segment transactions
An internally determined transfer price is set for all inter-entity sales. This price is re-set annually and is based on what would be realised in the event the sale was made to an external party at arm's length. All such transactions are eliminated on consolidation for the Group's financial statements.

Inter-segment loans payable and receivable are initially recognised at the consideration received net of transaction costs. If inter-segment loans are not on commercial terms, these are not adjusted to fair value based on market interest rates. This policy represents a departure from that applied to the statutory financial statements.

Segment assets
Where an asset is used across multiple segments, the asset is allocated to the segment that received the majority of economic value from the asset. In the majority of instances, segment assets are clearly identifiable on the basis of their nature and physical location.

Segment liabilities
Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to the Group as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

Segment performance

Segment revenue

	External Sales		**Inter-segment(s)**		**Other**		**Total**	
	2013 S'000	**2012 S'000**	**2013 S'000**	**2012 S'000**	**2013 S'000**	**2012 S'000**	**2013 S'000**	**2012 S'000**
Asia Pacific	2,795	2,252	51,473	42,393	1,034	1,312	55,302	45,956
Americas	43,100	33,355	4,417	4,167	-	-	47,517	37,522
Europe, Middle East, and Africa	12,686	10,436	899	85	-	-	13,585	10,521
Total of all segments							**116,404**	**93,999**
Eliminations							(56,788)	(46,645)
Unallocated							-	-
Consolidated							**59,616**	**47,354**

Notes to the Financial Statements

for the half-year ended 31 December 2013

NOTE 6: OPERATING SEGMENT (continued)

Segment net profit before tax

	2013	2012
	S'000	S'000
Asia Pacific	16,426	12,258
Americas	(201)	1,436
Europe, Middle East, and Africa	(1,631)	(60)
Total of all segments	**14,594**	**13,634**
Eliminations	-	(2,924)
Profit before income tax expense	**14,594**	**10,710**
Income tax expense	(3,424)	(2,930)
Profit after income tax expense	**11,170**	**7,780**

Segment assets and liabilities

	Assets		Liabilities	
	31 Dec 13 S'000	30 Jun 13 S'000	31 Dec 13 S'000	30 Jun 13 S'000
Asia Pacific	176,816	142,542	72,681	46,361
Americas	28,147	26,270	16,904	14,941
Europe, Middle East, and Africa	15,219	11,478	13,408	9,140
Total of all segments	**220,182**	**180,290**	**102,993**	**70,442**
Eliminations	(91,750)	(62,523)	(68,806)	(40,813)
Consolidated	**128,432**	**117,767**	**34,187**	**29,629**

Other segment information

	Asia Pacific		North America		Europe	
	2013 S'000	2012 S'000	2013 S'000	2012 S'000	2013 S'000	2012 S'000
Acquisition of segment assets						
- Plant and equipment	306	100	483	1,119	2,713	14
Depreciation and amortisation of segment assets						
- Plant and equipment	416	389	200	182	47	22
- Intangibles	94	105	-	-	2	2

NOTE 7: EVENTS AFTER REPORTING DATE

No matters or circumstances have arisen since the end of the financial half year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.